Is Moderna Stock A Buy On A Bullish Update For Its Cancer Vaccine?

Moderna stock has surged past a buy point after unveiling promising midstage test results for its personalized cancer vaccine in melanoma patients. X Patients who received the Moderna (MRNA) cancer vaccine in addition to Merck's (MRK) Keytruda were 44% less likely to relapse or die compared with…#covidvaccine #mrna #bntx #afundamentallookat #marketsmithcom #pfizer #phase3 #pfe #gettimelybuysell #importantly
Source: Reuters: Health - Category: Consumer Health News Source Type: news